Celcuity公司:Gedatolisib治疗方案总体耐受性良好,不良事件多为低级别

美股速递
Jun 02

根据一份提交给美国证券交易委员会(SEC)的文件,Celcuity Inc 在其临床研究中评估的Gedatolisib治疗方案展现出积极的耐受性特征。数据显示,该治疗方案总体上被患者良好耐受,所报告的大多数不良事件严重程度较低,属于低级别范畴。这一发现为后续的临床开发提供了支持性数据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10